Anne M Traynor

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
    Lung Cancer 64:51-9. 2009
  2. pmc A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI, 53792, USA
    Invest New Drugs 28:91-7. 2010
  3. pmc A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
    Anne M Traynor
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI 53792, USA
    Invest New Drugs 28:509-15. 2010
  4. pmc Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience
    Anne M Traynor
    Section of Hematology and Medical Oncology, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Head Neck 32:599-606. 2010
  5. pmc Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 29:316-22. 2011
  6. pmc Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Anne M Traynor
    University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 3103 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA
    Cancer Chemother Pharmacol 67:305-14. 2011
  7. pmc A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K6 568 CSC, Madison, WI, 53792, USA
    Invest New Drugs 31:1539-46. 2013
  8. pmc Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer
    Shannon E O'mahar
    Department of Medicine, Division of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA
    J Thorac Oncol 6:951-3. 2011
  9. pmc A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6 548 CSC, Madison, WI 53792, USA
    Invest New Drugs 31:943-8. 2013
  10. pmc Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
    Jill M Kolesar
    University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 72:661-7. 2013

Detail Information

Publications28

  1. pmc Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
    Lung Cancer 64:51-9. 2009
    ..The safety and tolerability of combination therapy with the EGFR inhibitor, gefitinib, and fulvestrant was explored...
  2. pmc A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI, 53792, USA
    Invest New Drugs 28:91-7. 2010
    ..The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC...
  3. pmc A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
    Anne M Traynor
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI 53792, USA
    Invest New Drugs 28:509-15. 2010
    ..To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of MN-209, a novel vascular disrupting agent, in patients with advanced solid tumors...
  4. pmc Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience
    Anne M Traynor
    Section of Hematology and Medical Oncology, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Head Neck 32:599-606. 2010
    ....
  5. pmc Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 29:316-22. 2011
    ..To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors...
  6. pmc Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Anne M Traynor
    University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 3103 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA
    Cancer Chemother Pharmacol 67:305-14. 2011
    ....
  7. pmc A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K6 568 CSC, Madison, WI, 53792, USA
    Invest New Drugs 31:1539-46. 2013
    ..A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors...
  8. pmc Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer
    Shannon E O'mahar
    Department of Medicine, Division of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA
    J Thorac Oncol 6:951-3. 2011
    ..We conducted a dose escalation study of this combination to determine the maximum tolerated dose of sunitinib in combination with a fixed dose of erlotinib and to evaluate the toxicities of this combination...
  9. pmc A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6 548 CSC, Madison, WI 53792, USA
    Invest New Drugs 31:943-8. 2013
    ..The recommended phase II dose of sorafenib in combination with 2DOC is 200 mg BID. There were infrequent grade 3 toxicities, most evident with sorafenib at 400 mg BID...
  10. pmc Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes
    Jill M Kolesar
    University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 72:661-7. 2013
    ..Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis...
  11. pmc A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 568, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 63:1147-56. 2009
    ..To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine administered in combination with doxorubicin...
  12. pmc Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
    ..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
  13. pmc Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    J Thorac Oncol 3:1018-25. 2008
    ..Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC...
  14. pmc Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    J Thorac Oncol 4:522-6. 2009
    ..Vorinostat is a small molecule inhibitor of histone deacetylase, and has shown preclinical activity in non-small cell lung cancer (NSCLC)...
  15. ncbi request reprint Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy
    Donald M Cannon
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    Head Neck 36:1120-5. 2014
    ..However, the significance of prolonged RTT with concurrent chemotherapy is less clear...
  16. doi request reprint Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
    Tien Hoang
    University of Wisconsin Carbone Cancer Center, Madison, WI, USA
    Invest New Drugs 32:195-9. 2014
    ..The primary objective of this phase II trial was to evaluate the efficacy and tolerability of vorinostat and bortezomib as third-line therapy in advanced non-small cell lung cancer (NSCLC) patients...
  17. pmc Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine
    Jill M Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Madison, 600 Highland Avenue, Room K4 554, Madison, WI 53792, USA
    J Inorg Biochem 102:693-8. 2008
    ..A potential source for the increase in the heme signal is cytochrome c released from the mitochondria. These results provide valuable insight into the in vivo mechanism of action of Triapine...
  18. pmc A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
    William R Schelman
    University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI, 53792, USA
    Invest New Drugs 32:295-302. 2014
    ....
  19. pmc Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Anne M Traynor
    Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lung Cancer 81:138-41. 2013
    ..We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC)...
  20. pmc Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer
    Donald M Cannon
    Donald M Cannon, Pranshu Mohindra, Søren M Bentzen, Anne M Traynor, Richard J Chappell, University of Wisconsin School of Medicine and Public Health, Madison, WI Minesh P Mehta, University of Maryland, Baltimore, MD Jarrod B Adkison, Southeast Alabama Medical Center, Dothan, AL Deepak Khuntia, Varian Medical Systems, Palo Alto, CA Wolfgang A Tomé, Albert Einstein College of Medicine, Bronx, NY George M Cannon, Intermountain Medical Center, Salt Lake City, UT Ranjini Tolakanahalli, Juravinski Cancer Center, Hamilton, Canada
    J Clin Oncol 31:4343-8. 2013
    ..The maximum-tolerated dose (MTD) with dose-escalated hypofractionation has not been adequately defined...
  21. pmc Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab
    Mari Iida
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Wisconsin Institute for Medical Research, Madison, WI, USA
    Cancer Biol Ther 14:481-91. 2013
    ....
  22. ncbi request reprint Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
    ....
  23. ncbi request reprint Systemic treatment of advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Drugs Today (Barc) 40:697-710. 2004
    ....
  24. ncbi request reprint Novel therapies for lung cancer
    Tien Hoang
    Department of Medicine, Medical Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Surg Oncol 11:229-41. 2002
    ....
  25. pmc The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients
    Tim J Kruser
    University of Wisconsin Comprehensive Cancer Center, Department of Human Oncology, Madison, Wisconsin, WI 53705, USA
    Expert Opin Investig Drugs 20:305-7. 2011
    ..Future studies of dasatinib in NSCLC should examine the agent in combination with EGFR inhibitors and/or cytotoxic chemotherapies...
  26. pmc Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform
    Benjamin P Casavant
    Department of Biomedical Engineering, Wisconsin Institutes for Medical Research, University of Wisconsin Madison, 1111 Highland Ave, Madison, WI, USA
    Lab Chip 14:99-105. 2013
    ....
  27. ncbi request reprint Metastasis of primary lung carcinoma to the breast: a systematic review of the literature
    Jennifer A Mirrielees
    Department of Surgery, Clinical Science Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
    J Surg Res 188:419-31. 2014
    ..The purpose of this systematic review was to summarize previously published case reports of primary lung carcinoma metastasis to the breast to assess common clinical and pathologic features and management strategies...
  28. pmc An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial
    David H Gustafson
    Center for Health Enhancement Systems Studies, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    Cancer 119:1744-51. 2013
    ....